1  constitute a good vaccine candidate against erysipelas.

2 gen causing infections, such as tonsillitis, erysipelas, and sepsis.

3  diverse range of invasive disease episodes (erysipelas, cellulitis, pneumonia, bacteremia, septic ar

4 of primary lymphedema, infection (cellulitis/erysipelas), Crohn's disease, obesity, cancer, and cance

5 d infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%.

6 mportant veterinary pathogen responsible for erysipelas in swine and a variety of diseases in animals

7 and skin-structure infections (cellulitis or erysipelas, major cutaneous abscess, or wound infection)

8 nfections (ABSSSIs), including cellulitis or erysipelas, major cutaneous abscesses, and wound infecti

9 gested to be associated with protection from erysipelas (n = 278) and streptococcal tonsillitis (n =

10 (BMI >/=30): HR = 3.64, 95% CI: 1.62, 8.18), erysipelas (obesity: HR = 5.19, 95% CI: 3.38, 7.95), and

11 of infection (wound infection, cellulitis or erysipelas, or major abscess) and receipt (yes or no) of

12  symptoms, and cellulitis other than typical erysipelas were predictors of nonresponse at day 3.